US equities
|
SPCX
$166.63
▲+4.83%
NVDA
$236.69
▲+1.17%
MU
$1,064.32
▼-0.98%
TSLA
$377.62
▲+1.90%
MSFT
$525.71
▲+1.58%
SNDK
$1,711.19
▼-0.51%
INTC
$117.18
▼-1.80%
META
$745.68
▲+2.42%
SPCX
$166.63
▲+4.83%
NVDA
$236.69
▲+1.17%
MU
$1,064.32
▼-0.98%
TSLA
$377.62
▲+1.90%
MSFT
$525.71
▲+1.58%
SNDK
$1,711.19
▼-0.51%
INTC
$117.18
▼-1.80%
META
$745.68
▲+2.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tiziana Life Sciences Ltd - Common Shares
(NQ:
TLSA
)
1.115
-0.005 (-0.45%)
Delayed Quote
Updated: 11:42 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd - Common Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
October 17, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences reports six-month PET scan results for MS patients
October 16, 2023
--News Direct--
Via
News Direct
Tiziana Life Sciences reports six-month PET scan results for MS patients
October 16, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
October 16, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana to Announce Six-Month Human Safety and Biomarker Data at the ECTRIMS Annual Congress, Following-Up from Positive Outcomes Data Presented in June
October 13, 2023
--News Direct--
Via
News Direct
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
↗
October 12, 2023
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea
Via
Benzinga
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
October 05, 2023
--News Direct--
Via
News Direct
Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal
↗
October 05, 2023
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday.
Via
Investor's Business Daily
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
↗
October 04, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Via
Benzinga
Latest AI Quantum Computing News And Company Stock Performances YTD
↗
October 03, 2023
The global quantum computing market is expected to grow at a CAGR of 38.3% over the next 5 years which presents an incredible opportunity for investors so which AI quantum computing stocks are...
Via
Talk Markets
Topics
Artificial Intelligence
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
↗
September 27, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab...
Via
Benzinga
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500
↗
September 22, 2023
Wood continued selling Tesla shares as TSLA forged a new buy point.
Via
Investor's Business Daily
Topics
Stocks
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car
↗
September 20, 2023
Oracle Corp (NYSE: ORCL) co-founder and Executive Chairman Larry Ellison recently made a surprising reveal during his CloudWorld talk.
Via
Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
↗
September 12, 2023
Tiziana Life Sciences Ltd.
Via
Benzinga
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
--News Direct--
Via
News Direct
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
↗
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
↗
August 16, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced...
Via
Benzinga
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
August 15, 2023
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 15, 2023
Via
Benzinga
Why Tiziana Life Sciences Stock (TLSA) Is Climbing
↗
August 15, 2023
Tiziana Life Sciences, Ltd (NASDAQ: TLSA) shares are trading higher Tuesday after the company announced that the FDA has cleared the Investigational New Drug (IND) application for intranasal foralumab...
Via
Benzinga
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
August 15, 2023
--News Direct--
Via
News Direct
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
